Spero Therapeutics, Inc.
NASDAQ:SPROBiotechnology
+$0.08 today
- Market cap
- $50.92M
- Beta
- 1.46
- P/E (TTM)
- 8.2
- EPS (TTM)
- $0.27
Volume 0.27M
Average 0.78M
SPRO Total Current Liabilities
All obligations due within one year.
Spero Therapeutics, Inc.NASDAQ: SPRO
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 81.2% from a year ago
Total current liabilities stood at $5.49M at the end of Q1 FY2026, down 81.2% from a year earlier and down 38.1% from the prior quarter. Over 3 fiscal years it compounded at -25.7% a year.
Context
- Total current liabilities amounted to 9.3% of total assets at the end of Q1 FY2026, down 28.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -81.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 8.87M USD
- Year-over-year change
- -81.9%
- 4-year CAGR
- -17.0%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.87M | -81.9% |
| FY2024 | 2024-12-31 | 49.07M | +32.1% |
| FY2023 | 2023-12-31 | 37.15M | +71.6% |
| FY2022 | 2022-12-31 | 21.65M | +16.0% |
| FY2021 | 2021-12-31 | 18.67M | — |
Total Current Liabilities vs competitors
How SPRO compares with its peers on the latest reported figures
- SPRO's Mar 2026 total current liabilities of $5.49M is the 9th highest of the 10 companies compared; the peer median is $10.24M.
- Its year-over-year change of -81.2% is the lowest of 10, against a peer median of -22.4%.
- Total current liabilities amounts to 9.3% of total assets for SPRO, versus a peer median of 16.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $37.92M | +38.8% | -23.3% | 76.2% | |
| Mar 2026 | $29.23M | +51.3% | +56.6% | 21.9% | |
| Mar 2026 | $19.34M | -38.2% | -39.1% | 16.4% | |
| Mar 2026 | $18.14M | +56.1% | +17.9% | 12.6% | |
| Mar 2026 | $10.24M | -22.4% | +7.6% | 3.8% | |
IRDOpus Genetics, Inc. | Mar 2026 | $9.34M | -61.5% | +41.4% | 14.0% |
| Mar 2026 | $6.07M | +26.9% | +27.3% | 20.4% | |
| Mar 2026 | $6.05M | -44.7% | +21.3% | 16.7% | |
| Mar 2026 | $5.49M | -81.2% | -25.7% | 9.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $4.72M | -48.4% | +9.5% | 53.0% |
| Peer median (excluding SPRO) | $10.24M | -22.4% | +17.9% | 16.7% | |
Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 112.58M | 109.11M | 76.33M | 52.89M | 40.27M |
| Short-term Investments | 33.82M | 0 | 0 | 0 | 0 |
| Net Receivables | 2.64M | 1.08M | 50.7M | 52.48M | 25.39M |
| Inventory | 0 | (4.46M) | 0 | 0 | 0 |
| Other Current Assets | 0 | 3.38M | 4.18M | 1.91M | 1.63M |
| Total Current Assets | 157.87M | 109.11M | 131.21M | 107.28M | 67.29M |
| Property, Plant & Equipment (Net) | 7.56M | 5.49M | 4.16M | 3.11M | 1.48M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 46.59M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 5.64M | 10.2M | 435K | 153K | 153K |
| Total Non-current Assets | 13.2M | 15.7M | 51.18M | 3.27M | 1.63M |
| Total Assets | 171.07M | 124.8M | 182.39M | 110.54M | 68.92M |
| Account Payables | 1.1M | 617K | 1.38M | 7.31M | 693K |
| Short-term Debt | 0 | 1.69M | 1.72M | 1.75M | 1.96M |
| Tax Payables | 0 | 0 | 387K | 174K | 383K |
| Deferred Revenue | 1.86M | 10.37M | 27.11M | 22.12M | 258K |
| Other Current Liabilities | 0 | 3.18M | 3.22M | 12.27M | 2.52M |
| Total Current Liabilities | 18.67M | 21.65M | 37.15M | 49.07M | 8.87M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 8.79M | 22.17M | 34.43M | 12.22M | 0 |
| Other Non-current Liabilities | 49.35M | 96K | 87K | 576K | 91K |
| Total Non-current Liabilities | 64.11M | 27.22M | 38.34M | 15.35M | 1.03M |
| Total Liabilities | 82.78M | 48.87M | 75.5M | 64.42M | 9.9M |
| Common Stock | 32K | 52K | 53K | 55K | 56K |
| Retained Earnings | (367.46M) | (413.88M) | (391.07M) | (459.64M) | (451.07M) |
| Accumulated OCI | (2K) | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 88.29M | 75.93M | 106.89M | 46.12M | 59.02M |
| Total Debt | 7.34M | 6.65M | 5.54M | 4.3M | 2.9M |
| Net Debt | (105.25M) | (102.46M) | (70.79M) | (48.59M) | (37.37M) |
Spero Therapeutics, Inc.
NASDAQ:SPRO
Intrinsic Alpha fair value
Locked
Current Price
$0.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.